Sanofi SNY
47.47 USD +2.14 (+4.72%)
At closeNov 5, 2026, 8:29 AM EST
47.54 +0.07 +0.15%
Pre-market · Nov 5, 8:29 AM ET
46.46 Day range 47.49
39.07 52-week range 52.68
- YTD
- -2.04%
- 1 year
- -3.12%
Analyst view
Consensus: buy
Buy
Price target (mean) 53.48 +12.7% upside
Now 47.47
- Target (low)
- 44.00
- Target (mean)
- 53.48
- Target (high)
- 63.00
Ratings (0m) 11 5 buy · 6 hold · 0 sell
- Strong buy0
- Buy5
- Hold6
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 10
- 3 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.86924 | 0.86924 – 0.86924 | 0.91289 | -4.8% | 12.91B | +14.2% | 1 |
| Current year | 5.03 | 5.03 – 5.04 | 4.67 | +7.8% | 48.49B | +11.1% | 2 |
| Next year | 5.33 | 4.96 – 5.56 | 5.03 | +5.9% | 51.01B | +5.2% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 16, 2026 | UBS | Downgrade | Buy | Neutral |
| Jan 6, 2026 | Barclays | Downgrade | Overweight | Equal-Weight |
| Dec 9, 2025 | Guggenheim | Downgrade | Buy | Neutral |
| Dec 8, 2025 | JP Morgan | Downgrade | Overweight | Neutral |
| Sep 8, 2025 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Sep 2, 2025 | Deutsche Bank | Upgrade | Hold | Buy |
| Aug 8, 2025 | JP Morgan | Upgrade | Neutral | Overweight |
| Mar 21, 2025 | Goldman Sachs | Initiated | — | Neutral |
| Jul 26, 2024 | Argus Research | Maintained | Buy | Buy |
| Jan 23, 2024 | Morgan Stanley | Initiated | — | Equal-Weight |
| Mar 27, 2023 | Argus Research | Maintained | — | Buy |
| Aug 12, 2022 | Deutsche Bank | Upgrade | Sell | Hold |
| Sep 27, 2021 | SVB Leerink | Upgrade | Market Perform | Outperform |
| Jan 15, 2021 | Deutsche Bank | Initiated | — | Sell |
| Mar 11, 2020 | Goldman Sachs | Upgrade | Neutral | Buy |
| Feb 19, 2020 | Argus Research | Maintained | — | Buy |
| Feb 11, 2020 | SVB Leerink | Initiated | — | Market Perform |
| Jan 6, 2020 | JP Morgan | Upgrade | Neutral | Overweight |
| Dec 6, 2019 | Barclays | Downgrade | Equal-Weight | Underweight |
| Sep 23, 2019 | Guggenheim | Upgrade | Neutral | Buy |
| Sep 3, 2019 | Bernstein | Initiated | — | Outperform |
| Dec 14, 2018 | Morgan Stanley | Initiated | — | Equal-Weight |
| Nov 8, 2018 | Argus Research | Maintained | Buy | Buy |
| Nov 1, 2018 | Barclays | Upgrade | Underweight | Equal-Weight |
| Sep 10, 2018 | B of A Securities | Upgrade | Neutral | Buy |
| Aug 24, 2018 | Argus Research | Maintained | Buy | Buy |
| Aug 10, 2018 | Citigroup | Upgrade | Neutral | Buy |
| Jan 23, 2018 | Barclays | Downgrade | Equal-Weight | Underweight |
| Nov 15, 2017 | Barclays | Upgrade | Underweight | Equal-Weight |
| Aug 30, 2017 | HSBC | Upgrade | Reduce | Hold |